1. Efficient α and β− radionuclide therapy targeting fibroblast activation protein-α in an aggressive preclinical mouse tumour model.
- Author
-
Ceuppens, Hannelore, Pombo Antunes, Ana Rita, Navarro, Laurent, Ertveldt, Thomas, Berdal, Marion, Nagachinta, Surasa, De Ridder, Kirsten, Lahoutte, Tony, Keyaerts, Marleen, Devoogdt, Nick, Goyvaerts, Cleo, D'Huyvetter, Matthias, and Breckpot, Karine
- Subjects
PROGRAMMED death-ligand 1 ,IMMUNE checkpoint proteins ,MEDICAL sciences ,TREATMENT effectiveness ,LABORATORY mice - Abstract
Purpose: Targeted radionuclide therapy (TRT) is a cancer treatment with relative therapeutic efficacy across various cancer types. We studied the therapeutic potential of TRT using fibroblast activation protein-α (FAP) targeting sdAbs (4AH29) labelled with
225 Ac or131 I in immunocompetent mice in a human FAP (hFAP) expressing lung cancer mouse model. We further explored the combination of TRT with programmed cell death ligand 1 (PD-L1) immune checkpoint blockade (ICB). Methods: We studied the biodistribution and tumour uptake of [131 I]I-GMIB-4AH29 and [225 Ac]Ac-DOTA-4AH29 by ex vivo γ-counting. Therapeutic efficacy of [131 I]I-GMIB-4AH29 and [225 Ac]Ac-DOTA-4AH29 was evaluated in an immunocompetent mouse model. Flow cytometry analysis of tumours from [225 Ac]Ac-DOTA-4AH29 treated mice was performed. Treatment with [225 Ac]Ac-DOTA-4AH29 was repeated in combination with PD-L1 ICB. Results: The biodistribution showed high tumour uptake of [131 I]I-GMIB-4AH29 with 3.5 ± 0.5% IA/g 1 h post-injection (p.i.) decreasing to 0.9 ± 0.1% IA/g after 24 h. Tumour uptake of [225 Ac]Ac-DOTA-4AH29 was also relevant with 2.1 ± 0.5% IA/g 1 h p.i. with a less steep decrease to 1.7 ± 0.2% IA/g after 24 h. Survival was significantly improved after treatment with low and high doses [131 I]I-GMIB-4AH29 or [225 Ac]Ac-DOTA-4AH29 compared to vehicle solution. Moreover, we observed significantly higher PD-L1 expression in tumours of mice treated with [225 Ac]Ac-DOTA-4AH29 compared to vehicle solution. Therefore, we combined high dose [225 Ac]Ac-DOTA-4AH29 with PD-L1 ICB showing therapeutic synergy. Conclusion: [225 Ac]Ac-DOTA-4AH29 and [131 I]I-GMIB-4AH29 exhibit high and persistent tumour targeting, translating into prolonged survival in mice bearing aggressive tumours. Moreover, we demonstrate that the combination of PD-L1 ICB with [225 Ac]Ac-DOTA-4AH29 TRT enhances its therapeutic efficacy. [ABSTRACT FROM AUTHOR]- Published
- 2025
- Full Text
- View/download PDF